Personalized Medicine
321 articles
More Research Needed for Pancreatic Cancer Immunotherapy
Dr. Luis Diaz provides a status check for immunotherapy treatments for pancreatic cancer, including an explanation of different types.
Standard of Care Plus
Dr. Allyson Ocean explains why pancreatic cancer patients should consider clinical trials, which go beyond standard of care.
Overcoming Challenges to Vaccine Immunotherapy
Dr. Elizabeth Jaffee explains the challenges facing the scientists developing vaccine-based immunotherapy for pancreatic cancer.
A Simple Blood Test for Early Detection of Eight Cancers Shows Promise
Dr. Anne Marie Lennon explains the CancerSEEK blood test, a liquid biopsy in clinical trials for early detection of eight cancers, including pancreatic.
Collaborative Multi-Center Immunotherapy Trial Targets CD40 and PD-1
Dr. Mark O’Hara outlines a collaborative clinical trial of two immunotherapy agents–a checkpoint inhibitor and a monoclonal antibody–plus standard chemotherapy.
Immunology Researchers Solve a Mystery of Metastasis
Physician and researcher Douglas Fearon and his lab have a possible explanation for how cancer cells metastasize, and the role surgery may play in this process.
Adjuvant Chemotherapy with Modified FOLFIRINOX Regimen Improves Survival
A French clinical trial showed that adjuvant chemotherapy (given after surgery) with modified FOLFIRINOX improves survival of pancreatic cancer patients.
Tough Tortoise of a Drug Beating Metastatic Pancreatic Cancer
Rexahn Pharmaceuticals is testing RX-3117, a slow-releasing drug similar to gemcitabine, in a clinical trial for metastatic pancreatic cancer patients.
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Pancreatic Microbiome May Hold the Key To Better Treatment
Dr. Deirdre Cohen’s research into the pancreatic microbiome has found that gut bacteria may directly influence the effectiveness of immunotherapy.
The Link Between Depression and Pancreatic Cancer
Drs. Annette Stanton and Michael Irwin outline the links between depression and pancreatic cancer, both as a symptom of the disease and post-diagnosis.
The Diabetes and Pancreatic Cancer Connection
Professor Dr. Suresh Chari explains the link between newly on-set diabetes as an indication of pancreatic cancer. Read Dr. Chari’s findings to learn more.
CAR T Cell Trial Targets Mesothelin
In an immunotherapy clinical trial, Dr. Mark O’Hara is using CAR T cells to attack mesothelin-expressing tumor cells in pancreatic cancer.
Studying One Family’s Mutations May Change Pancreatic Cancer Treatment and Prevention
Dr. Sahar Nissim is studying the genetic mutations in one family predisposed to pancreatic cancer, to find new ways to combat the disease.